Step 3: Sanofi commits up to $100M to opt-in on Alnylam’s PhIII RNAi hemophilia trial
Alnylam is stepping up to the starting line for a Phase III study of its hemophilia drug fitusiran with Sanofi on board as a partner. The pharma company lined up the opt-in rights under their earlier deal to buy a minority stake in the biotech for $700 million. And Sanofi is now committed to providing $75 million in development and regulatory milestones following a $25 million upfront due when Phase III starts in early 2017.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.